Your project is run entirely by Adimab scientists, with regular updates to keep you informed at every step. Antibody panels are delivered to you for evaluation in your lab, and additional engineering is available to further refine promising candidates. This phase-based model is capital efficient while supporting rapid progress toward high-quality therapeutics ready for the clinic.